CRIS Current Research Information System

BISELLI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.095
AS - Asia 5.473
EU - Europa 3.840
AF - Africa 323
SA - Sud America 267
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 16.009
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.027
VN - Vietnam 1.988
SG - Singapore 1.300
CN - Cina 1.087
IT - Italia 845
GB - Regno Unito 733
SE - Svezia 506
DE - Germania 470
HK - Hong Kong 354
IN - India 248
FR - Francia 231
BR - Brasile 179
IE - Irlanda 164
NL - Olanda 162
RU - Federazione Russa 160
UA - Ucraina 131
CH - Svizzera 116
TG - Togo 100
JO - Giordania 81
KR - Corea 76
ZA - Sudafrica 75
FI - Finlandia 72
JP - Giappone 68
CI - Costa d'Avorio 67
BD - Bangladesh 56
EE - Estonia 53
BG - Bulgaria 46
TH - Thailandia 41
AT - Austria 35
PH - Filippine 35
CA - Canada 32
SC - Seychelles 29
BE - Belgio 26
AR - Argentina 25
ID - Indonesia 23
IR - Iran 23
NG - Nigeria 20
EC - Ecuador 19
ES - Italia 17
PL - Polonia 17
MX - Messico 16
CL - Cile 15
TW - Taiwan 14
HR - Croazia 13
PK - Pakistan 13
IQ - Iraq 12
TR - Turchia 11
CO - Colombia 10
ET - Etiopia 10
UZ - Uzbekistan 9
VE - Venezuela 8
AU - Australia 7
LT - Lituania 7
SA - Arabia Saudita 7
MY - Malesia 6
CZ - Repubblica Ceca 5
LB - Libano 5
MA - Marocco 5
CR - Costa Rica 4
DK - Danimarca 4
JM - Giamaica 4
PT - Portogallo 4
PY - Paraguay 4
RO - Romania 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
EG - Egitto 3
GR - Grecia 3
HN - Honduras 3
MK - Macedonia 3
NI - Nicaragua 3
NP - Nepal 3
UY - Uruguay 3
BO - Bolivia 2
CG - Congo 2
EU - Europa 2
IL - Israele 2
LU - Lussemburgo 2
MM - Myanmar 2
MU - Mauritius 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CM - Camerun 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GH - Ghana 1
HU - Ungheria 1
IS - Islanda 1
KZ - Kazakistan 1
LV - Lettonia 1
Totale 16.001
Salva come PNG Salva come JPEG
Città #
Singapore 891
Ashburn 665
Southend 628
Fairfield 590
Chandler 510
Ho Chi Minh City 423
Dong Ket 415
Hanoi 384
Hong Kong 315
Bologna 298
San Jose 291
Woodbridge 286
Houston 280
Seattle 264
Wilmington 223
Cambridge 212
Santa Clara 200
Princeton 172
Dublin 162
Ann Arbor 154
Hefei 153
Boardman 135
Beijing 131
Bern 105
Lomé 100
Los Angeles 94
Lauterbourg 85
Dallas 82
New York 81
Amman 80
Jacksonville 79
Da Nang 76
Council Bluffs 70
Redmond 70
Abidjan 67
Westminster 66
Milan 62
Padova 57
Seoul 57
Tokyo 57
Berlin 56
Haiphong 54
Helsinki 54
Nanjing 51
Shenyang 44
Buffalo 43
Sofia 43
Munich 41
Jinan 40
Florence 36
San Diego 36
São Paulo 36
Rome 34
Turin 33
Amsterdam 31
Frankfurt am Main 31
Saint Petersburg 31
Guangzhou 28
Hải Dương 27
Vienna 27
Brussels 26
Redondo Beach 26
Tianjin 26
Bremen 25
Falkenstein 23
Nanchang 23
Shanghai 23
Hebei 22
London 22
Changsha 21
Des Moines 21
Bến Tre 20
Phoenix 20
Abeokuta 19
Hangzhou 19
Biên Hòa 18
Can Tho 17
Chicago 17
Medford 16
Paris 16
Zhengzhou 16
Brooklyn 15
Johannesburg 15
Mülheim 15
San Francisco 15
Dearborn 14
Orem 14
The Dalles 14
Wuhan 14
Bangkok 13
Bengaluru 13
Bắc Ninh 13
Norwalk 13
Vũng Tàu 13
Washington 13
Falls Church 12
Jiaxing 12
Nha Trang 12
Olalla 12
Turku 12
Totale 10.536
Salva come PNG Salva come JPEG
Nome #
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 328
Optimization of pineapple juice amount used as a negative oral contrast agent in magnetic resonance cholangiopancreatography 296
Monofocal hepatocellular carcinoma: How much does size matter? 295
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 288
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 268
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 252
Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. 250
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 244
Pattern of macrovascular invasion in hepatocellular carcinoma 242
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 237
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 235
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 233
Chronic prostatitis/pelvic pain syndrome: MRI findings and clinical correlations. 233
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation. 229
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 227
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 223
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 222
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 219
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 219
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 212
The changing scenario of hepatocellular carcinoma in Italy: an update 209
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 209
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 208
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 208
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 205
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 204
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 200
Metabolic disorders across hepatocellular carcinoma in Italy 200
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 200
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 199
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 196
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 195
Posttranscriptional changes of serum albumin: clinical and prognostic meaning in hospitalized patients with cirrhosis. 194
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 192
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 188
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 187
Liver transplantation for patients with alcoholic liver disease: an open question 184
What is the best fruit juice to use as a negative oral contrast agent in magnetic resonance cholangiopancreatography? 184
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 184
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned. 181
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 178
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. 175
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 174
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 172
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 172
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 171
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 170
Two years Mycophenolate Mofetil plus low dose calcineurin inhibitor for renal dysfunction after liver transplantation. 168
In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C 168
Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis 165
null 164
Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. 162
Trattamento dell’epatopatia alcolica 161
New MRI series for kidney evaluation: Saving time and money 161
Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma 160
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 156
Magnetic Resonance Enterography Reinvented: Exploring the Potential of a New Natural Beverage as an Alternative to Polyethylene Glycol Solution 156
Years of life that could be saved from prevention of hepatocellular carcinoma. 155
Reply to “Re: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma—A Propensity Analysis” 155
Authors’ reply: Comment to “Liver transplantation for patients with alcoholic liver disease: An open question” 153
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 153
The Gastropack Access System as a Model to Access Gastroenterology Services for Gastroscopy Appropriateness in Patients with Upper Gastrointestinal Symptoms: A Comparison with the Open Access System 152
The MELD score in patients awaiting liver transplant: strengths and weaknesses. 152
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 151
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 147
The evolutionary scenario of hepatocellular carcinoma in Italy: an update. 147
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? 147
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? 144
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study 142
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study 138
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 134
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE. 124
PEGYLATED INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION 121
Hepatocellular carcinoma surveillance: an open question 121
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival 119
Hepatic artery stenosis in liver transplanted patients treated with pegylated Interferon alpha-2b and Ribavirin 119
Liver injury with novel oral anticoagulants: Assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system 117
null 117
Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. 116
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis 115
Sustained and focused HBV-nucleocapsid-specific T cell immunity in liver transplant recipients compared to individuals with chronic and self-limited HBV infection. 111
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE 99
null 95
null 83
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 82
Prognosis of untreated hepatocellular carcinoma. 82
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma 78
Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents? 75
null 72
Increased survival after sustained virological response in liver transplanted patients with HCV recurrence: taking-up a challenge for the hepatologist. 68
Increased survival after sustained virological response in liver transplanted patients with HCV recurrence: taking-up a challenge for the hepatologist. 68
A modified Child-Turcotte-Pugh (CTP) for selection of candidates to liver transplantation (LT) with low model for end-stage liver disease score (MELD). 65
A modified Child-Turcotte-Pugh (CTP) for selection of patients affected by cirrhosis candidates for liver transplantation (LT) with low model for end-stage liver disease score (MELD) 64
Seven score systems to evaluate candidates to orthotopic liver transplantation: which is the winner? 60
Natremia and Child-Turcotte-Pugh (CTP) score may improve the selection of candidates for liver transplantation (LT) with lower model for end-stage liver disease score (MELD) 54
Natremia and Child-Turcotte-Pugh (CTP) may improve the selection of candidates for liver transplantation (LT) with lower model for end-stage liver disease score (MELD). 48
Totale 16.262
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.179
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.179
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021571 0 0 0 0 0 0 0 0 0 0 0 571
2021/20221.849 133 83 81 153 138 101 45 145 66 145 491 268
2022/20232.136 194 338 99 286 113 179 79 105 360 66 160 157
2023/2024621 64 87 45 50 48 131 21 61 28 31 35 20
2024/20252.016 80 286 179 179 277 110 192 71 15 175 97 355
2025/20265.579 362 370 412 314 491 279 1.139 211 1.105 457 213 226
Totale 16.262